Osteoporosis International

, Volume 24, Issue 4, pp 1161–1168 | Cite as

The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study

  • L-A. Fraser
  • W. D. Leslie
  • L. E. Targownik
  • A. Papaioannou
  • J. D. Adachi
  • CaMos Research Group
Original Article

Abstract

Summary

A large Canadian cohort was studied over 10 years to see if proton pump inhibitor (PPI) use increased the risk of sustaining a fragility fracture. We found an increased risk of fracture in individuals who used PPIs. The risk remained after controlling for other known fracture risk factors.

Introduction

Multiple retrospective studies have linked proton pump inhibitor use with increased risk of fragility fracture. We prospectively studied the association between PPI use and fracture in a large cohort over a 10-year period while controlling for known fracture risk factors.

Methods

We studied 9,423 participants in the Canadian Multicenter Osteoporosis Study. The cohort was formed in 1995–1997 and followed for 10 years with monitoring for incident nontraumatic fracture and PPI use. Cox regression analyses were used to assess the association between PPI use and incident fracture risk.

Results

PPI use, coded as a time-dependent variable, was associated with a shorter time to first nontraumatic fracture, hazard ratio (HR) = 1.75 (95 % confidence interval (CI) 1.41–2.17, p < 0.001). After controlling for multiple risk factors, including femoral neck bone density, the association remained significant, HR = 1.40 (95 % CI 1.11–1.77, p = 0.004). Similar results were obtained after controlling for bisphosphonate use, using PPI “ever” use, or when the outcome was restricted to hip fracture.

Conclusions

In this large prospective population-based cohort study, we found an association between PPI use and increased risk of fragility fracture. Although the increased risk found was modest, this finding is important, given the high prevalence of PPI use and the excess morbidity and mortality associated with osteoporosis-related fractures.

Keywords

Fracture Osteoporosis Proton pump inhibitors Risk factor 

Notes

Acknowledgments

The authors thank all the participants in the CaMos study, whose participation made this research possible. The Canadian Multicentre Osteoporosis Study was funded by the Canadian Institutes of Health Research (CIHR), Merck Frosst Canada Ltd., Eli Lilly Canada Inc., Novartis Pharmaceuticals Inc., the Alliance: Sanofi-Aventis and Procter & Gamble Pharmaceuticals Canada Inc., Servier Canada Inc., Amgen Canada Inc., the Dairy Farmers of Canada, and the Arthritis Society. The funding sources had no role in the design, conduct, analysis, interpretation, or presentation of our study.

Conflicts of interest

LAF has been on the speaker’s bureau for Amgen. WDL has received speaker fees and unrestricted research grants from Merck Frosst; unrestricted research grants from Sanofi-Aventis, Warner Chilcott, Novartis, Amgen, and Genzyme and from advisory boards for Genzyme, Novartis, and Amgen. LET, advisory boards and grants for investigator initiated research from Astra Zeneca Canada and Janssen Canada. AP has been a consultant/speaker for Amgen, Aventis, Eli Lilly, Merck Frosst, Novartis, Procter & Gamble, Servier, and Wyeth-Ayerst; conducted clinical trials for Eli Lilly, Merck Frosst, Novartis, Procter & Gamble, and Sanofi-Aventis; and received unrestricted grants from Amgen, Eli Lilly, Merck Frosst, Procter & Gamble, and Sanofi-Aventis. JDA has received research support and has been a consultant of Amgen, Astra Zeneca, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Nycomed, Pfizer, Procter & Gamble, Roche, Sanofi-Aventis, Servier, Warner Chilcott, and Wyeth.

References

  1. 1.
    Berger C, Goltzman D, Langsetmo L, Joseph L, Kreiger N, Tenenhouse A et al (2010) Peak bone mass from longitudinal data: implications for the prevalence, pathophysiology, and diagnosis of osteoporosis. J Bone Miner Res 25:1948–1957PubMedCrossRefGoogle Scholar
  2. 2.
    Papaioannou A, Kennedy CC, Ioannidis G, Sawka A, Hopman WM, Pickard L et al (2009) The impact of incident fractures on health-related quality of life: 5 years of data from the Canadian Multicentre Osteoporosis Study. Osteoporos Int 20:703–714PubMedCrossRefGoogle Scholar
  3. 3.
    Adachi JD, Loannidis G, Berger C, Joseph L, Papaioannou A, Pickard L et al (2001) The influences of osteoporotic fractures on health-related quality of life in community-dwelling men and women across Canada. Osteoporos Int 12:903–908PubMedCrossRefGoogle Scholar
  4. 4.
    Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301:513–521PubMedCrossRefGoogle Scholar
  5. 5.
    Becker DJ, Kilgore ML, Morrisey MA (2010) The societal burden of osteoporosis. Curr Rheumatol Rep 12:186–191PubMedCrossRefGoogle Scholar
  6. 6.
    Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993–1000PubMedCrossRefGoogle Scholar
  7. 7.
    Richards JB, Papaioannou A, Adachi JD, Joseph L, Whitson HE, Prior JC et al (2007) Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 167:188–194PubMedCrossRefGoogle Scholar
  8. 8.
    Jetté N, Lix LM, Metge CJ, Prior HJ, McChesney J, Leslie WD (2011) Association of antiepileptic drugs with nontraumatic fractures: a population-based analysis. Arch Neurol 68:107–112PubMedCrossRefGoogle Scholar
  9. 9.
    Mazziotti G, Canalis E, Giustina A (2010) Drug-induced osteoporosis: mechanisms and clinical implications. Am J Med 123:877–884PubMedCrossRefGoogle Scholar
  10. 10.
    Yu EW, Bauer SR, Bain PA, Bauer DC (2011) Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med 124:519–526PubMedCrossRefGoogle Scholar
  11. 11.
    U.S. Food and Drug Administration (2011). FDA Drug Safety Communication. possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. Accessed at http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpateintsandproviders/ucm213206.htm on July 1, 2011.
  12. 12.
    Heidelbaugh JJ, Goldberg KL, Inadomi JM (2009) Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk. Am J Gastroenterol 104(Suppl 2):27–32CrossRefGoogle Scholar
  13. 13.
    Katz MH (2010) Failing the acid test: benefits of proton pump inhibitors may not justify the risks for many users. Arch Intern Med 170:747–748PubMedCrossRefGoogle Scholar
  14. 14.
    Howell MD, Novack V, Grgurich P, Soulliard D, Novack L, Pencina M et al (2010) Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 170:784–790PubMedCrossRefGoogle Scholar
  15. 15.
    Hoorn EJ, van der Hoek J, de Man RA, Kuipers EJ, Bolwerk C, Zietse R (2010) A case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis 56:112–116PubMedCrossRefGoogle Scholar
  16. 16.
    Lin SL, Chang HM, Liu CP, Chou LP, Chan JW (2011) Clinical evidence of interaction between clopidogrel and proton pump inhibitors. World J Cardiol 3:153–164PubMedCrossRefGoogle Scholar
  17. 17.
    Sheen E, Triadafilopoulos G (2011) Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci 56:931–950PubMedCrossRefGoogle Scholar
  18. 18.
    Kaye JA, Jick H (2008) Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 28:951–959PubMedCrossRefGoogle Scholar
  19. 19.
    Targownik LE, Leslie WD (2011) The relationship among proton pump inhibitors, bone disease and fracture. Expert Opin Drug Saf 10:901–912PubMedCrossRefGoogle Scholar
  20. 20.
    Kreiger N, Tenenhouse A, Joseph L, Mackenzie T, Poliquin S, Brown JP et al (1999) The Canadian Multicentre Osteoporosis Study (CaMos): background, rationale, methods. Can J Aging 18:376–387CrossRefGoogle Scholar
  21. 21.
    Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12:417–427PubMedCrossRefGoogle Scholar
  22. 22.
    Bessette L, Ste-Marie L-G, Jean S, Davison KS, Beaulieu M, Baranci M et al (2008) The care gap in diagnosis and treatment of women with a fragility fracture. Osteoporos Int 19:79–86PubMedCrossRefGoogle Scholar
  23. 23.
    Fisher LD, Lin DY (1999) Time-dependent covariates in the cox proportional-hazards regression model. Annu Rev Public Health 20:145–157PubMedCrossRefGoogle Scholar
  24. 24.
    Roux C, Briot K, Gossec L, Kolta S, Blenk T, Felsenberg D et al (2009) Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int 84:13–19PubMedCrossRefGoogle Scholar
  25. 25.
    Roughead EE, McGeechan K, Sayer GP (2004) Bisphosphonate use and subsequent prescription of acid suppressants. Br J Clin Pharmacol 57:813–816PubMedCrossRefGoogle Scholar
  26. 26.
    McGowan B, Bennett K, Barry M, Canny M (2008) The utilisation and expenditure of medicines for the prophylaxis and treatment of osteoporosis. Ir Med J 101:38–41PubMedGoogle Scholar
  27. 27.
    Pouwels S, Lalmohamed A, Souverein P, Cooper C, Veldt BJ, Leufkens HG et al (2011) Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study. Osteoporos Int 22(3):903–10PubMedCrossRefGoogle Scholar
  28. 28.
    Yang YX, Lewis JD, Epstein S, Metz DC (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296:2947–2953PubMedCrossRefGoogle Scholar
  29. 29.
    Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD (2008) Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 179:319–326PubMedGoogle Scholar
  30. 30.
    Ensrud KE, Duong T, Cauley JA, Heaney RP, Wolf RL, Harris E et al (2000) Low fractional calcium absorption increases the risk for hip fracture in women with low calcium intake. Ann Intern Med 132:345–353PubMedGoogle Scholar
  31. 31.
    Bo-Linn GW, Davis GR, Buddrus DJ, Morawski SG, Santa Ana C, Fordtran JS (1984) An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium. J Clin Invest 73:640–647PubMedCrossRefGoogle Scholar
  32. 32.
    Serfaty-Lacrosniere C, Wood RJ, Voytko D, Saltzman JR, Pedrosa M, Sepe TE et al (1995) Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. J Am Coll Nutr 14:364–368PubMedGoogle Scholar
  33. 33.
    Recker RR (1985) Calcium absorption and achlorhydria. N Engl J Med 313:70–73PubMedCrossRefGoogle Scholar
  34. 34.
    O'Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ (2005) Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 118:778–781PubMedCrossRefGoogle Scholar
  35. 35.
    McLean RR, Jacques PF, Selhub J, Tucker KL, Samelson EJ, Broe KE et al (2004) Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med 350:2042–2049PubMedCrossRefGoogle Scholar
  36. 36.
    Targownik LE, Lix LM, Leung S, Leslie WD (2010) Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 138:896–904PubMedCrossRefGoogle Scholar
  37. 37.
    Yu EW, Blackwell T, Ensrud KE, Hillier TA, Lane NE, Orwoll E et al (2008) Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int 83:251–259PubMedCrossRefGoogle Scholar
  38. 38.
    Gray SL, LaCroix AZ, Larson J (2010) Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women’s Health Initiative. Arch Intern Med 170:765–771PubMedCrossRefGoogle Scholar
  39. 39.
    Targownik LE, Leslie WD, Davison S, Goltzmen D, Jamal S, Josse RG, et al Proton pump inhibitors are associated with decreased bone mineral density. Amer J Gastroenterol. 106(Suppl 2):405.Google Scholar
  40. 40.
    Mizunashi K, Furukawa Y, Katano K, Abe K (1993) Effect of omeprazole, an inhibitor of H+, K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int 53:21–25PubMedCrossRefGoogle Scholar
  41. 41.
    Sheraly AR, Lickorish D, Sarraf F, Davies JE (2009) Use of gastrointestinal proton pump inhibitors to regulate osteoclast-mediated resorption of calcium phosphate cements in vivo. Curr Drug Deliv 6:192–198PubMedCrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2012

Authors and Affiliations

  • L-A. Fraser
    • 1
    • 4
  • W. D. Leslie
    • 2
  • L. E. Targownik
    • 2
  • A. Papaioannou
    • 3
  • J. D. Adachi
    • 3
  • CaMos Research Group
  1. 1.Department of MedicineUniversity of Western OntarioLondonCanada
  2. 2.Department of MedicineUniversity of ManitobaWinnipegCanada
  3. 3.Department of MedicineMcMaster UniversityHamiltonCanada
  4. 4.Division of Endocrinology and MetabolismSt. Joseph’s Health CareLondonCanada

Personalised recommendations